Continuous Enhancement Planning (CEPs) and reporting for 2024/25 academic year is to be completed under the 2024/25 Code of practice for continuous enhancement review: taught programmes 2024/25 (PDF) ...

This suggests that GLP1 agonists are promising agents to reduce risk of chronic liver disease progression in patients with concurrent type 2 diabetes, although this needs to be corroborated in ...